Compression-Induced Phase Transitions of Bicalutamide.
Kollidon®VA64
amorphous solid dispersions
bicalutamide
compression
dissolution
physical stability
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
09 May 2020
09 May 2020
Historique:
received:
16
03
2020
revised:
27
04
2020
accepted:
06
05
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
14
5
2020
Statut:
epublish
Résumé
The formation of solid dispersions with the amorphous drug dispersed in the polymeric matrix improves the dissolution characteristics of poorly soluble drugs. Although they provide an improved absorption after oral administration, the recrystallization, which can occur upon absorption of moisture or during solidification and other formulation stages, serves as a major challenge. This work aims at understanding the amorphization-recrystallization changes of bicalutamide. Amorphous solid dispersions with poly(vinylpyrrolidone-
Identifiants
pubmed: 32397432
pii: pharmaceutics12050438
doi: 10.3390/pharmaceutics12050438
pmc: PMC7284452
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Narodowe Centrum Nauki
ID : 2015/16/W/NZ7/00404
Références
Eur J Pharm Sci. 2010 Jan 31;39(1-3):125-33
pubmed: 19932176
Mol Pharm. 2009 Sep-Oct;6(5):1492-505
pubmed: 19634917
Eur J Pharm Biopharm. 2012 May;81(1):207-13
pubmed: 22293573
Eur J Pharm Biopharm. 2018 Mar;124:147-157
pubmed: 29269154
Int J Pharm. 2013 Aug 30;453(1):253-84
pubmed: 22820134
J Pharm Sci. 2012 Apr;101(4):1355-77
pubmed: 22213468
Mol Pharm. 2019 Aug 5;16(8):3626-3635
pubmed: 31287704
Int J Pharm. 2012 Jul 1;430(1-2):253-7
pubmed: 22486956
Mol Pharm. 2018 Sep 4;15(9):3969-3978
pubmed: 30052449
Eur J Pharm Biopharm. 1999 Jul;48(1):59-65
pubmed: 10477330
Pharmaceutics. 2018 Oct 18;10(4):
pubmed: 30340413
Int J Pharm. 2017 Nov 30;533(2):470-479
pubmed: 28363855
J Pharm Sci. 2006 Dec;95(12):2692-705
pubmed: 16892209
J Pharm Sci. 2010 Mar;99(3):1322-35
pubmed: 19798757
Clin Pharmacokinet. 2004;43(13):855-78
pubmed: 15509184
Mol Pharm. 2015 Oct 5;12(10):3628-38
pubmed: 26323061
Int J Pharm. 2007 Jan 10;328(2):112-8
pubmed: 16978811
J Pharm Sci. 2016 Sep;105(9):2527-2544
pubmed: 26886314
Mol Pharm. 2018 Jun 4;15(6):2455-2465
pubmed: 29738666
Mol Pharm. 2016 Jun 6;13(6):1879-93
pubmed: 27092396
Eur J Pharm Biopharm. 2019 Oct;143:8-17
pubmed: 31398439
Int J Pharm. 2018 May 5;542(1-2):18-26
pubmed: 29481948
Mol Pharm. 2019 Apr 1;16(4):1742-1750
pubmed: 30848603
J Pharm Sci. 2008 Aug;97(8):3222-32
pubmed: 18085711
Pharm Res. 2012 Sep;29(9):2489-98
pubmed: 22638868
Mol Pharm. 2018 May 7;15(5):1928-1940
pubmed: 29584436
Eur J Pharm Sci. 2019 Aug 1;136:104947
pubmed: 31170526
Mol Pharm. 2016 Apr 4;13(4):1308-16
pubmed: 26981876
J Biol Chem. 2002 Jul 19;277(29):26321-6
pubmed: 12015321
Mol Pharm. 2017 Oct 2;14(10):3370-3380
pubmed: 28787567
Eur J Pharm Sci. 2017 Dec 15;110:117-123
pubmed: 28666849
Mol Pharm. 2017 Apr 3;14(4):1071-1081
pubmed: 28231007
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):799-813
pubmed: 24056053
Mol Pharm. 2014 Apr 7;11(4):1102-8
pubmed: 24533914
Eur J Pharm Biopharm. 2006 Jun;63(2):103-14
pubmed: 16675209
Eur J Pharm Biopharm. 2019 Mar;136:231-239
pubmed: 30703545
Drug Dev Ind Pharm. 2008 Jan;34(1):95-106
pubmed: 18214761
J Pharm Sci. 2017 Jan;106(1):5-27
pubmed: 27372552